Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology

Shots:

• With the acquisition of Loxo by Eli Lilly, Bayer exercises its option and get exclusive WW rights to develop and commercialize Vitrakvi and BAY 2731954 including in the US. Loxo to receive royalties on sales of product (Ex-the US)
• Acc to Nov,2017 deal Bayer, and Loxo collaborated to jointly develop and commercialize larotrectinib and BAY 2731954 (LOXO-195) in the US with equal cost and profit sharing
• Vitrakvi (larotrectinib) is an oral TRK inhibitor developed in collaboration with Bayer, targeted for solid tumors with NTRK gene fusion in adult and pediatric patients and has received FDA approval in Nov, 2018. BAY 2731954 (LOXO-195) is an oral drug evaluated in P-I/II for TRK fusion cancers that are resistant to initial TRK therapy

Click here to read full press release/ article| Ref: Bayer | Image: Bayer